SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease
In patients with T2D and ASCVD, treatment with SGLT2-I and GLP-1RA, especially in combination, is associated with a substantial reduction in mortality. These findings highlight significant gaps in implementation and the urgent need to optimize use of evidence-based therapies in this high-risk population.
Authors
- Ziad Arow (ORCID: https://orcid.org/0000-0002-4157-4225)
- Ela Giladi (ORCID: https://orcid.org/0000-0001-9867-8570)
- Tzipi Hornik‐Lurie (ORCID: https://orcid.org/0000-0002-2122-5116)
- Hana Vaknin‐Assa (ORCID: https://orcid.org/0000-0001-6935-9765)
- Yoav Arnson (ORCID: https://orcid.org/0000-0002-0397-1756)
- Ranin Hilu (ORCID: https://orcid.org/0009-0005-9559-719X)
- David Pereg (ORCID: https://orcid.org/0000-0002-3394-2032)
- Abid R. Assali
Institutions
- Tel Aviv University (IL)
- Meir Medical Center (IL)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1186/s12933-025-02874-7
- Citations
- 6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 7.77